Clinical Use of Hematopoietic Growth Factors in the Myelodysplastic Syndromes

References

• Ganser A., Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol/Oncol Clin North Amer 1992; 6: 607–618
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Ganser A., Heimpel H. “Atypical” leukemias: preleukemia. smoldering leukemia and hypoplastic leukemia. Rec, Res Cancer Res 1984; 93: 69–101
   PubMedGoogle Scholar
• Bennett J. M., Catovsky D., Daniel M., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Jacobs A. Genetic lesions in preleukemia. Leukemica 1991; 5: 277–282
   PubMed Web of Science ®Google Scholar
• Prchal J. T., Trockmorton D. W., Carrol A. J., et al. A common progenitor for myeloid and lymphoid cells. Nature 1978; 274: 590–591
   PubMed Web of Science ®Google Scholar
• Raza A., Gerer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoictic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
   PubMed Web of Science ®Google Scholar
• Raza A., Mundle S., Iftikhar A., et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hamatol 1995; 48: 143–154
   PubMed Web of Science ®Google Scholar
• Bartram C. R. Molecular genetic aspects of myelodysplastic syndromes. Hamatol/Oncol Clin North Amer 1992; 6: 557–570
   PubMed Web of Science ®Google Scholar
• van Karnp H., de Pijper C., Verlaan-de Vries M., et al. Longitudinal analysis of point mutations of the N-ras proto-oncogcne in patients with myelodysplasia using archived blood smears. Blood 1992; 79: 1266–1270
   PubMed Web of Science ®Google Scholar
• Paquette R. L., Landaw E. M., Pierre R. V., et al. N-ras muiations arc associated with poor prognosis and increased risk of leukemia in inyelodysplastic syndrome. Blood 1993; 82: 590–599
   PubMed Web of Science ®Google Scholar
• van Kamp H., Fibbe W. E., Jansen R. P. M., et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992; 1774–1780
   PubMed Web of Science ®Google Scholar
• Janssen J. W. G., Buschle M., Layton M., et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotential stem cell origin. Blood 1989; 73: 248–254
   PubMed Web of Science ®Google Scholar
• Hoefsloot L. H., van Amelsvoort M. P., Broeders C. C. A. M., Backx B., van der Plas D. C., Touw I. P., Löwenberg B. Impaired erythropoiesis in inyelodysplastic syndrome is associated with the inability of erythropoietin receptor to activate STAT-5. Blood 1995; 86(Suppl 1)271A
   Google Scholar
• Aul C., Arning M., Runde V., Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 1991; 15: 571–575
   PubMed Web of Science ®Google Scholar
• Bowen D. T., Jacobs A., Cotes M. P., et al. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1990; 44: 30–32
   PubMed Web of Science ®Google Scholar
• Jacobs A., Janowska-Wieczorek A., Caro J., et al. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989; 73: 36–39
   PubMed Web of Science ®Google Scholar
• Verhoef G. E., De Schouwer P., Ceuppens J. L., et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6: 1268–1272
   PubMed Web of Science ®Google Scholar
• Völkers B., Ganser A., Greher J., et al. Effect of tumor necrosis factor-alpha on human hematopoietic progenitor cells. Onkologic 1989; 12: 109–115
   PubMed Web of Science ®Google Scholar
• Ohmori S., Ohmori M., Yaniagiahi M., Okuma M. MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. Br J Haematol 1993; 83: 388–391
   PubMed Web of Science ®Google Scholar
• Aul C., Gattermann N., Schneider W. Agerelated incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358–367
   PubMed Web of Science ®Google Scholar
• Williamson P. J., Kruger A. R., Reynolds P. J., et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743–745
   PubMed Web of Science ®Google Scholar
• Blank J., Lange B. Preleukemia in children. J Pediatr 1981; 98: 565
   PubMed Web of Science ®Google Scholar
• Aul C., Schneider W. Myelodysplastic syndromes. A prognostic factor analysis of 221 untreated patients. Blut 1983; 57: 234
   Google Scholar
• Mufti G. J., Stevens J. R., Oscier D. G., et al. Myelodysplastic syndromes. A scoring system with prognostic significance. Br J Haemtal 1985; 59: 425
   PubMed Web of Science ®Google Scholar
• Sanz G. F., Sanz M. A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning Ireatinent in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395
   PubMed Web of Science ®Google Scholar
• Tricot G., Criel A., Verwilghen R. L. Thrombocytopenia as presenting symptom of preleukaemia in 3 patients. Scand J Haematol 1982; 28: 243
   PubMedGoogle Scholar
• Mufti G. J., Galton D. A. C. Myelodysplastic syndromes. Natural history and features of prognostic significance. Clin Haematol 1986; 15: 953
   PubMedGoogle Scholar
• Boogaerts M. A., Nelissen V., Roelant C., Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55: 217
   PubMed Web of Science ®Google Scholar
• Schofield K. P., Stone P. C. W., Kelsey P., et al. Quantitative cytochemistry of blood neutrophils in myelodysplastic syndromes and chronic granulocytic leukemia. Cell Biochem Function 1983; 1: 92
   PubMed Web of Science ®Google Scholar
• Scott C. S., Cahill A., Bynoe A. G., et al. Eaterase cytochemistry in primary myelodysplastic syndromes and megalobiastic anaemias: Demonstration of abnormal staining patterns associated with dysmyelopoiesis. Br J Haematol 1983; 55: 411
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jouet J. P., Zandecki M., et al. Chronic and subacute myelornonocytic leukaemia in the adult. A report of 60 cases with special references to prognostic features. Br J Haematol 1987; 65: 101
   PubMed Web of Science ®Google Scholar
• Ribera J. M., Cervantes F., Rozman C. A. A multivariate analysis of prognostic factors in chronic myelonionocytic leukaemia according to the FAB criteria. Br J Haematol 1987; 65: 3077
   Web of Science ®Google Scholar
• Lintula R., Rasi V., Ikkala E., et al. Platelet function in preleukaemia. Scand J Haematol 1981; 96: 65
   Google Scholar
• Maldonado J. E., Pierre R. V. The platelets in preleukemia and myelomonocytic leukcmia: Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc 1975; 50: 573
   PubMed Web of Science ®Google Scholar
• Cauola M., Barosi C., Gobbi P. G., et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71: 305
   PubMed Web of Science ®Google Scholar
• Gattermann N., Aul C., Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74: 45
   PubMed Web of Science ®Google Scholar
• Streeter R. R., Presant C. A., Reinhard E. Prognostic significance of thrombocytosis in idiopathic sideroblastic anemia. Blood 1977; 50: 427
   PubMed Web of Science ®Google Scholar
• Kerkhofs H., Hermans I., Haak H. L., Leeksma C. H. W. Utility of the FAB classification for myelodysplastic syndromes. Investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65: 73
   PubMed Web of Science ®Google Scholar
• Tricot G., Vlietinck R., Boogaerts M. A., et al. Prognostic factors in the myelodysplastic syndromes. Importance of initial data on peripheral blood counts. bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985; 60: 19
   PubMed Web of Science ®Google Scholar
• Varela G. L., Chuang C., Woll J. E., Bennett J. M. Modifications in the classification of primary myclodysplastic syndromes. The addition of a scoring system. Haematol, Oncol 1985; 3: 55
   PubMed Web of Science ®Google Scholar
• Pomeroy C., Oken M. M., Rydell R. E., Filiee G. A. Infection in the myelodysplaslic syndromes. Am J Med 1991; 90: 338
   PubMed Web of Science ®Google Scholar
• Mecucci C., van den Berghe H. Cytogenetics. Haematol/Oncol Clin North Amer 1992; 6: 523–541
   PubMed Web of Science ®Google Scholar
• Richert-Boe K. E., Bagby G. C. In vitro hematopoiesis in myelodysplasia: Iiquid and soft-gel culture studies. Haematol/Oncol Clin North Amer 1902; 6: 543–556
   Google Scholar
• Tennant G. B., Bowen D. T., Jacobs A. Colonycluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia. Br J Haematol 1991; 77: 296–300
   PubMed Web of Science ®Google Scholar
• Löffler H., Schmitz N., Gassmann W. Intensive chemotherapy and bone marrow tratisplantation for myelodysplastic syndromes. Haematol/Oncol Clin North Amer 1992; 6: 619–632
   PubMed Web of Science ®Google Scholar
• Paquette R. L., Koeffler H. P. Differentiation therapy. Haematol/Oncol Clin North Amer 1992; 6: 687–706
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Fisher L. D., et al. Allogcneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Dührsen U., Hossfeld D. Hematopoietic growth factors and the treatment of tumor-associated anemias. Ann Hematol 1994; 69: 213–221
   PubMed Web of Science ®Google Scholar
• Ganser A., Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Haematol/Oncol Clin North Amer 1992; 6: 633–654
   PubMed Web of Science ®Google Scholar
• Ganser A. Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Curr Opinion Hematol 1995; 2: 204–209
   PubMedGoogle Scholar
• Legare R. D., Gilliland D. G. Myelodysplastic syndrome. Curr Opinion Hematol 1995; 2: 283–292
   PubMedGoogle Scholar
• Löwenberg B., Touw I. P. Hematopoietic growth factora and their receptors in acute leukemia. Blood 1993; 81: 281–292
   PubMed Web of Science ®Google Scholar
• Negrin R. S., Haeuber D. H., Nagler A., et al. Maintenance therapy of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 3643
   Google Scholar
• Kobayashi Y., Okabe T., Ozawa K., et al. Treatment of myelodysplastic syndromes with human granulocyte colony-stimulating factor: a preliminary report. Am J Med 1989; 86: 178–182
   PubMed Web of Science ®Google Scholar
• Negrin R. S., Stein K., Vardiman J., et al. Treatment of the ancmia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737–743
   PubMed Web of Science ®Google Scholar
• Yuo A., Kitagawa S., Okabe T., et al. Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 1987; 70: 404–411
   PubMed Web of Science ®Google Scholar
• Greenberg P., Taylor K., Larson R., et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood. 1993; 82(Suppl 1)196a
   Google Scholar
• Greenberg P., Negrin R., Nagler A., et al. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stiniulating factor. Int J Cell Cloning 1990; 8(Suppl 1)293–302
   PubMedGoogle Scholar
• Negrin R., Haeubre D. H., Nagler A., et al. Treatment of myelodysplastic syndromes with recomhinant human granukxyte colony-stimulating factor. A phase I/I I trial. Ann Intern Med 1989; 110: 976–984
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Hirashima K., Asano S., et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78: 378–384
   PubMed Web of Science ®Google Scholar
• Ganser A., Seipelt G., Verbeeck W., et al. Effcet of combination therapy with all-trans retinoic acid and recombi-mant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994; 8: 369–375
   PubMed Web of Science ®Google Scholar
• Aul C., Runde V., Gattermann N. All-rans retinoic acid in patients with myclodysplastic synthomes: results of a pilot study. Blood 1993; 82: 1967–1974
   Google Scholar
• Kurzrock R., Estey E., Talpaz M. All-trans retinoic acid: Tolerance and biologic effects in myclodysplastic syndronics. J Clin Oncol 1903; 11: 1489–1496
   Google Scholar
• Ohno R., Naor T., Hirano M., et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood 1993; 81: 1152–1154
   PubMed Web of Science ®Google Scholar
• Visani G., Cenacchi A., Tasi P., et al. All-trans retinoic acid iniprovcs erythropoiesis in myelodysplastic syndromes: a case report. Br J Haematol 1992; 81: 444–448
   PubMed Web of Science ®Google Scholar
• Maurer A. B., Ganser A., Seipelt G., et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with niyelodysplastic syndromes during treatment with all-trans retinoic acid and haemitopoietic growth factors. Br J Haematol 1995; 89: 449–456
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Talpaz M., Gomez J. A., et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of lowover high-dose administration in selected patients. Br J Haematol 1991; 78: 352–358
   PubMed Web of Science ®Google Scholar
• Rose C., Wattel E., Bastion Y., et al. 'Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 1994; 8: 1458–1462
   PubMed Web of Science ®Google Scholar
• Schuster M. W., Thompson J. A., Larson R., et al. Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS). Blood 1995; 86(Suppl 1)338a
   Google Scholar
• Delmer A., Karmochkine M., Cadiou M., et al. Recurrent spleen enlargement during cyclic granulocyte-niaerophae colony-stimulating factor therapy for myelodysplastic syndromes. Am J Haematol 1990; 34: 73–74
   PubMed Web of Science ®Google Scholar
• Wilson P. A., Ayscue L. H., Jones G. R., et al. Bone marrow histiocytic proliferation in association with colony-stimulating factor therapy. Am J Clin Pathol 1993; 99: 311–313
   PubMed Web of Science ®Google Scholar
• Antin J. H., Smith B. R., Holmes W., et al. Phase I/II study of recombinant human granulocyte-macrophage colony stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705–713
   PubMed Web of Science ®Google Scholar
• Ganser A., Völkers B., Greher J., et al. Recombinant human granulocyte-macrophage colony-stmulating factor in patients with myelodysplastic syndromes-a phase I/II trial. Blood 1989; 73: 31–37
   PubMed Web of Science ®Google Scholar
• Rosenfeld C. S., Sulecki M., Evans C., et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Haematol 1991; 19: 273–277
   PubMed Web of Science ®Google Scholar
• Thompson J. A., Douglas J. L., Kidd P., et al. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7: 629–637
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Kellagher M. J., Keating M., et al. Phase I study of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. N Eng J Med. 1988; 317: 1545–1552
   Web of Science ®Google Scholar
• Maurer A. B., Ganser A., Buhl R., et al. Restoration of impaired cytokine secretion from patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 1993; 7: 189–195
   Google Scholar
• Bhalla K., Birkhofer M., Arlin Z., et al. Effect of recombinant GM-CSF and IL-3 on the metabolism of cytosine arabinoside in normal and leukemic human hone marrow cells. Leukemia 1988; 2: 810–813
   PubMed Web of Science ®Google Scholar
• Brach M., Klein H., Platzer E., et al. Effect of interleukin-3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 1990; 18: 748–753
   PubMed Web of Science ®Google Scholar
• Ganser A., Seipelt G., Eder M., et al. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 1992; 19(Suppl 4)95–101
   PubMedGoogle Scholar
• Van der Lely N., De Witte T., Muus P., et al. Prolonged exposure to cyrosirie arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol 1991; 19: 267–272
   PubMed Web of Science ®Google Scholar
• Ganser A., Ottmann O. G., Schulz G., et al. Recomhinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. Onkologie 1989; 12: 13–15
   PubMed Web of Science ®Google Scholar
• Höffken K., Overkamp F., Stirbu J., et al. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie 1990; 13: 33–37
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Ganser A., Ottmann O. G., et al. Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on lcukcmic blast cells in patients with myelodysplastic syndromes. Haematol Blood Transfusion 1990; 33: 763–769
   PubMedGoogle Scholar
• Gerhartz H. H., Marcus R., Delmer A., et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994; 8: 16–23
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Simon R. Low dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years experience. Sem Oncol 1987; 14(Suppl 1)126–133
   PubMedGoogle Scholar
• Ganser A., Lindemann A., Seipelt G., et al. The effect of recombinant human interleukin-3 in patients with normal hemopoiesis and in patients with secondary bone marrow failure. Blood 1990; 76: 666–676
   PubMed Web of Science ®Google Scholar
• Bemstein S. F., Gilliland D. G., Aster J., et al. A randomized trial of two doses of recombinant interleukin-3 in patients with myelodysplastic syndrome. Blood 1992; 80(Suppl. 1)410a
   Google Scholar
• Dunbar C. E., Smith D., Kimball J., et al. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood 1990; 76(Suppl 1)141a
   Google Scholar
• Ganser A., Seipelt G., Lindernann A., et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455462
   Google Scholar
• Ganser A., Ottmann O. G., Seipelt G., et al. Effect of long-term treatment with recombinant human interlcukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7: 696–701
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Talpaz M., Estrov Z., et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9: 1241–1250
   PubMed Web of Science ®Google Scholar
• Nimer S. D., Pacquette R. L., Ireland P., et al. A phase I/II study of the interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994; 22: 875–880
   PubMed Web of Science ®Google Scholar
• Seipelt G., Ganser A., Duranceyk H., et al. Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Ann Hematol 1994; 68: 167–170
   PubMed Web of Science ®Google Scholar
• Zwierzina H., Herold M., Geiller D., et al. Soluble interleukin-2 (IL-2) receptor expression in patients with myelodysplastic syndromes is induced by granulocyte-macrophage colony-stimulating factor and IL-3. Blood 1991; 77: 2195–2796
   Google Scholar
• Seipelt G., Ganser A., Duranceyk H., et al. Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993; 84: 749–751
   PubMed Web of Science ®Google Scholar
• Gordon M. S., Nemunaitis J., Hoffman R., et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066–3076
   PubMed Web of Science ®Google Scholar
• Bowen D., Ehmer B., Neubert P., et al. The clearance of a single iv. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991; 19: 613–616
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E. Efficacy of erythropoietin in the myeiodyspiastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67–71
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Cooper S., Williams D. E., et al. Growth characteristics of marrow hernatopoietic progenitor/ precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyt-macrophage colony-stimulating factor. Exp Hematol 1988; 16: 594–602
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Broxmeyer H. E., Spitzer G., et al. Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 1989; 74: 1491–1498
   PubMed Web of Science ®Google Scholar
• Ottmann O. G., Ganser A., Seipelt G., et al. Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 1990; 76: 1494–1502
   PubMed Web of Science ®Google Scholar
• Rafanelli D., Grossi A., Longo G., et al. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 1992; 6: 323–327
   PubMed Web of Science ®Google Scholar
• Schouten H. C., Vellenga E., van Rhenen D. J., et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 1991; 5: 432–436
   PubMed Web of Science ®Google Scholar
• Van Kamp H., Tineke C., Prinsze-Postema T. C., et al. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 1991; 78: 488–493
   PubMed Web of Science ®Google Scholar
• Verhoef G., Van Den Berghe H., Boogaerts M. Cytogenelic effects on cells derived from palients with myelodysplasiic syndromes during treatment with hematopoietic growlh factors. Leutkemia 1992; 6: 766–769
   PubMedGoogle Scholar
• Anastasi J., Feng J., LeBcau M. M., et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridirytion: Lineage, response to growth factor therapy and clonal expansion. Blood 1993; 81: 1580–1585
   PubMed Web of Science ®Google Scholar
• Ohyashiki K., Ohyashiki J. H., Toyama K., et al. Hematologic and cytogenetic findings in myelodysplasfic syntlrnines treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res 1989; 80: 848–854
   PubMedGoogle Scholar
• Ganser A., Janssen J. W. G., Ottmann O. G., et al. In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic diaorders. Leutkemia 1991; 5: 487–492
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E., Birgegard G., Carlsson M., et al. A combination oi granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11: 221–228
   PubMed Web of Science ®Google Scholar
• Imamura M., Kobayashi M., Kobayashi S., et al. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and crythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68: 163–166
   PubMed Web of Science ®Google Scholar
• Ghio K., Balleari E., Ballestrero A., et al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta. Haematol 1993; 90: 58–64
   PubMed Web of Science ®Google Scholar
• Hansen P. B., Hippe E., Hellström-Lindberg E., et al. Recombinant human granulocytemncrophage colony-stimulating factor plus erythropoietin may improve anemia in selected palients with myelodysplasia. Am J Hematol 1993; 44: 229–236
   PubMed Web of Science ®Google Scholar
• List A. L., Noyes W., Power J., et al. Combined treatment of myelodysplaslic syndromes (MDS) with recombinam human interleukin-3 (IL-3) and crythropoietin (EPO). Blood 1993; 82(Suppl 1)377a
   Google Scholar
• Verhoef G., Demuynek H., Zachée P., et al. Treatment of myelodysplastic syndromes (MDS) with the combination of inlerleukin-3 and erythropoietin. Blood 1993; 82(Suppl 1)377a
   Google Scholar
• Ganser A., Lindeinann A., Ottmann O. G., et al. Sequential in vivo treatment with two recombinant human hematopnietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis. Blood 1992; 79: 2583–2591
   PubMed Web of Science ®Google Scholar
• Nand S., Sosman J., Godwin J. E., et al. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994; 83: 357–360
   PubMed Web of Science ®Google Scholar
• Ganser A., Maurer A., Contzen C., et al. Improved multilineage rehponse of heniatopoiesia in patients with myelodysplastic syndromes to a combination therapy with all trans-retinoic acid, granulocyte colony-stimulating factor, eythropoietin, and α-tocopherol. Ann Hematol 1996; 72: 237–244
   PubMed Web of Science ®Google Scholar
• Dombret H., Chastang C., Fenaux P., et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678–1683
   PubMed Web of Science ®Google Scholar
• Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte-colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 477–871
   Web of Science ®Google Scholar
• Rowe J. M., Andersen J., Mazza J., et al. A ran domized placebo-controlled phase III study of granulocytcmacrophage colony-stimulating factor in adult patients (>55 to 70 yeai-s of age) with acute inyelogenous Ieuhemia. A study of the Eastern Cooperalive Oncnlogy Group (E 1490). Blood 1995; 86: 457–462
   PubMed Web of Science ®Google Scholar
• Stone R., Berg D. T., George S. L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671–1677
   PubMed Web of Science ®Google Scholar
• Ganser A., Heil G., Kolbe K., et al. Aggressive chemntherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, suhaeute or secondary acute inyeloid leukemia—initial results. Ann Hematol 1993; 66: 123–125
   PubMed Web of Science ®Google Scholar
• Demuynck H., Delforge M., Verhoef G. E. G., et al. Feasability of peripheral blood progenitor cell hat-vest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996; 92: 351–359
   PubMed Web of Science ®Google Scholar
• Dellorge M., Demuynck H., Vandenberghe P., et al. Polyclonal primitive hematopoietic progenitors can he detected in mobilized peripheral blood from patients with high-risk myelndysplastic syndromes. Blood 1995; 86: 3660–3667
   PubMed Web of Science ®Google Scholar
• Estey E. H., Kurzrock R., Talpaz M., et al. Effects of low doses of recombinant human granulocyle-macrophage colony-stimulating factor (GM-CSF) in palients with myelodysplastic syndromes. Br J Haematol 1991; 77: 291–295
   PubMed Web of Science ®Google Scholar
• Estey E. H., Thall P., Andreef M., et al. Use of granulocyte colony-stimulating factor belore, during, and after fludarabine plus cytarabinc induction therapy of newly diagnosed acute myelogennus leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–678
   PubMed Web of Science ®Google Scholar
• Bernell P., Kimby E., Hast R. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodyspliastic syndromes: a pilot study. Leukemia 1994; 8: 1631–1639
   PubMed Web of Science ®Google Scholar
• Kaczmarski R. S., Mufti G. J. Low-doe filgrastim therapy for chronic neutropenia. N Engl J Med 1993; 329: 1280–1281
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Nakahata T., Shihata A., et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulalitig factor in patients with myelodysplastic syndrome. Leuk Lymphoma 1995; 18: 457–463
   PubMed Web of Science ®Google Scholar
• Herrmann F., Lindemann A., Klein H., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989; 3: 335–338
   PubMed Web of Science ®Google Scholar
• Willemze R., Visani G., de Witte Th., et al. A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia. Blood 1990; 76(Suppl 1)337a
   Google Scholar
• Gradishar W. J., LeBcau M. M., O'Laughlin R., et al. Clinical and cytogenetic responses to granulocytemacrophage colony-stimulating factor in therapy-related myclodysplasia. Blood 1992; 80: 2463–2470
   PubMed Web of Science ®Google Scholar
• Takahasha M., Yoshida Y., Kaku K., et al. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol 1993; 89: 189–194
   PubMed Web of Science ®Google Scholar
• Bessho M., Jinnai I., Maisuda A., et al. Improvement of anemia by recombinant human erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990; 8: 445–458
   PubMedGoogle Scholar
• Osier W., Krumwieh D., Brune T., et al. Evaluation of erythropoietin (EPO) in the treatment of patients with myelodysplastic syndromes (MDS)-preclinical data supporting a rationale for sequential therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) and EPO. J Cancer Clin Oncol 1990; 116: 280, Suppl
   Google Scholar
• Stebler C., Tichelli A., Dazzi H., et al. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1990; 18: 1204–1208
   PubMed Web of Science ®Google Scholar
• Bowen D., Culligan D., Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991; 77: 419–423
   PubMed Web of Science ®Google Scholar
• Hellström E., Birgegard G., Locker D., et al. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991; 47: 355–360
   PubMed Web of Science ®Google Scholar
• Stein R. S., Abels R. I., Krantz S. B. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658–1663
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Talpaz M., Estey E., et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1991; 5: 985–990
   PubMed Web of Science ®Google Scholar
• Verhoef G. E., Zachee P., Ferrant A., et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythro kinetic assessment. Ann Hematol 1992; 64: 16–21
   PubMed Web of Science ®Google Scholar
• Shepherd J. D., Curie C. J., Sparling T. G., et al. Erythropoietin therapy of myelodysplastic syndromes. Blood 1992; 79: 1891–1892
   PubMed Web of Science ®Google Scholar
• Cazzola M., Ponchio L., Beguin Y., et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood 1992; 79: 29–37
   PubMed Web of Science ®Google Scholar
• Goy A., Belanger C., Casadevall N., et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993; 84: 232–237
   PubMed Web of Science ®Google Scholar
• Ludwig H., Fritz E., Leitgeb C., et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161–167
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Anzai N., Kawabata H., et al. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. Ann Hematol 1993; 66: 175–180
   PubMed Web of Science ®Google Scholar
• Zeigler Z. R., Jones D., Rosenfeld C. S., et al. 1993
   Google Scholar
• Stenke L., Wallvik J., Celsing F., et al. Prediction of response to treatment with recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993; 7: 1324–1327
   PubMed Web of Science ®Google Scholar
• Shapiro S., Gershon H., Roaenbaum H., et al. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin. Leukemia 1993; 7: 1328–1333
   PubMed Web of Science ®Google Scholar
• Razzano M., Caslini C., Cortellazzo S., et al. Therapy with human recombinant ciythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1992; 81: 628–630
   PubMed Web of Science ®Google Scholar
• Aloe Spiriti M. A., Petti M. C., Latagliata R., et al. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?. Leuk Lymphoma 1993; 9: 79–83
   PubMed Web of Science ®Google Scholar
• Mohr B., Herrmann R., Huhn D. Recombinant human erythropoietin in patients with myelodysplastic syndromes and myelofibrosis. Acta Haematol 1993; 90: 65–70
   PubMed Web of Science ®Google Scholar
• Isnard F., Najman A., Jaar B., et al. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk Lymphoma 1994; 12: 307–314
   PubMed Web of Science ®Google Scholar
• Stone R. M., Bernstein S. H., Demetri G., et al. Treatment with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res 1994; 18: 769–776
   PubMed Web of Science ®Google Scholar
• Rose E. H., Abels R. I., Nelson R. A., et al. The use of r-HuEpo in the treatment of anemia related to myelodysplasia (MDS). Br J Haematol 1995; 89: 831–837
   PubMed Web of Science ®Google Scholar
• Backx B., Broeders L., Touw I., Löwenberg B. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 1993; 7: 75–79
   PubMed Web of Science ®Google Scholar